Do Birth Control Pills or Hormone Therapy Raise the Risk of a Retinal Vein Occlusion?
Get Your Eyes Checked the Same Day If Your Vision Suddenly Changes
If you take hormonal birth control or menopause hormone therapy and your sight changes suddenly, treat it as urgent. Call your eye doctor and ask for a same day visit. If you cannot reach one, go to an emergency room. Get care right away for any of these:
- Sudden vision loss in one eye, whether it is the whole picture or a missing patch.
- A gray or dark curtain, or a shadow, that moves across your sight.
- Blurring in one eye that does not clear when you blink or rest.
- A burst of new floaters, or flashing lights, in one eye.
- Sudden double vision, or a bad headache with the vision change.
Most sudden blur turns out to be something mild, like dry eye or a migraine aura. A blocked retinal vein is far less common. But it is one of the causes doctors need to rule out fast, because early care protects more of your sight. A same day check costs you an afternoon. Waiting can cost you sight you do not get back.
Combined hormonal contraceptives raise the chance of a blood clot in the body as a whole, not only in the eye1. So it helps to know the full set of danger signs. Call 911 or go to an emergency room without delay for swelling, pain, or warmth in one calf; chest pain or trouble breathing; coughing up blood; a sudden severe headache unlike your usual ones; or weakness, numbness, or slurred speech on one side.
The label the FDA requires for combined birth control pills tells clinicians to stop the pill and check for a retinal vein clot right away when there is unexplained loss of vision1. That is a rule for the prescriber, not a task for you to carry out alone.
If a warning sign sends you in for care, bring your pill pack, patch, or ring box so the team can see the exact product and dose. Do not quit hormonal contraception on your own before you talk with the clinician who prescribed it. Stopping without a backup plan carries its own risk, since pregnancy raises the chance of a venous clot as much as or more than combined pills do1. The safe order: same day eye check first, then a call to your prescriber.
Hormones and Retinal Vein Occlusion at a Glance
For combined hormonal birth control, yes, slightly. For menopause hormone therapy, a large US study found no detectable increase. A Danish national study followed 2,208,172 women aged 15 to 49 for a median of 10 years. Women currently using hormonal contraception had roughly 1.4 times the rate of retinal vein occlusion of women not using it. That came to about 5 extra cases for every 1,000,000 women followed for a year2. The increase is real enough to measure across a whole country, and still a small addition to an uncommon event.
They are not the same drug at the same dose. Combined contraceptives use synthetic estrogen at a level chosen to block ovulation. Menopause hormone therapy uses lower doses, often through the skin, to ease symptoms. One US study looked at 205,304 women who filled a prescription for female hormone therapy and 755,462 women who did not. It found no measurable increase in retinal vein occlusion or in retinal artery occlusion3. So the headline is split: a small signal for the pill, no signal so far for menopause hormone therapy.
If you use hormonal contraception and have no clotting risk factors, this is not a reason to stop. It is a reason to know the warning signs above and to keep your blood pressure in a healthy range. If you smoke, are over 35, get migraines with aura, or have had a clot, ask your prescriber which method suits you best.
What a Retinal Vein Occlusion Is and Who Gets One
The retina is the light-sensing tissue lining the back of your eye. It drains used blood through veins. When a clot blocks the main retinal vein, blood and fluid leak into the retina, and the macula, the small central zone you read with, swells4. The swelling, not the clot itself, is what usually blurs vision. That matters, because the swelling can often be treated.
A central retinal vein occlusion blocks the main drainage vein at the optic nerve and tends to affect the whole field of one eye. A branch retinal vein occlusion blocks a smaller tributary and leaks into one wedge of the retina, and vision can dim suddenly or over a few hours to days5. The branch form is roughly five times as common as the central form6.
Retinal vein occlusion is uncommon at any age and rare in the years when most people use contraception. Pooled data from 17 population studies put the worldwide rate in adults aged 30 to 89 at about 8 of every 1,000 people, about 6 of every 1,000 for the branch form and about 1 of every 1,000 for the central form6. Pooled data from 15 studies covering 68,751 adults estimated 16.4 million adults affected worldwide7. About 9 of every 10 central occlusions occur in people over 508.
What Causes a Retinal Vein Occlusion, and Where Hormones Fit In
The strongest risk factors have nothing to do with hormones. In the pooled population data, high blood pressure carried close to three times the odds of retinal vein occlusion, a prior heart attack about twice the odds, and each added decade of age about 1.6 times the odds6. The Academy's practice guideline names high blood pressure, diabetes, and raised blood lipids as the changeable risk factors to manage with your primary care clinician9.
The estrogen in a combined pill is what drives the better known warnings about clots in the legs and lungs. A retinal vein sits at the far end of that same story. The FDA-required label puts the risk of a venous clot in users of combined pills at 3 to 9 cases for every 10,000 women per year. It notes the risk is highest in the first year of use, and when restarting after a break of 4 weeks or longer1.
The Danish registers track nearly every woman of reproductive age through prescription and hospital records. Across 23,882,016 person-years, current hormonal contraception use was linked to about 1.4 times the rate of retinal vein occlusion. The rate of retinal artery occlusion was not clearly raised2. This is one study in one country, so read it as a consistent signal rather than a settled number.
In the US claims study, the rate of retinal vein occlusion in women who filled a hormone therapy prescription was not detectably different from the rate in women who did not. The authors concluded that a history of hormone therapy may not be relevant when evaluating someone who has had a retinal occlusion3. Follow-up was short, so it speaks more clearly to the first months of use than to decades of it.
Which Hormonal Methods Carry More Risk, and Who Is Most Affected
Not every hormonal method behaves the same way. In the Danish cohort, combined pills with 30 to 40 micrograms of estrogen showed about 1.6 times the rate of retinal vein occlusion, while pills with 20 micrograms showed no increase2. Dose is one of the few parts of a prescription you and your prescriber can adjust, so it is a fair thing to raise at your next visit.
Methods without estrogen come out differently in the same data. Hormonal intrauterine devices showed no increased rate of retinal vein occlusion in the Danish cohort2. These devices release progestin mainly inside the uterus, with little estrogen effect on the body. For someone who cannot take estrogen, this is often the practical route.
Every figure in the table below comes from that one Danish cohort2, so read it as a single large study rather than a settled consensus.
| Method | Estrogen | Rate vs non-use |
|---|---|---|
| Combined pill, 30 to 40 micrograms | Yes, standard dose | About 1.6 times |
| Combined pill, 20 micrograms | Yes, lower dose | No increase measured |
| Hormonal intrauterine device | No | No increase measured |
Smoking and estrogen are a genuinely risky pair, and here the guidance is firm. The FDA-required label states that smoking raises the risk of serious heart and blood vessel events from combined pill use, that the risk climbs with age and with the number of cigarettes, and that combined pills are contraindicated in women over 35 who smoke1. If that is you, ask about an estrogen-free method.
Several histories move you out of the small-added-risk group. The label lists a history of deep vein clots or lung clots, known clotting disorders, stroke or coronary artery disease, uncontrolled high blood pressure, diabetes with blood vessel damage, and migraine with focal neurological symptoms among the contraindications to combined pills1. Inherited clotting problems such as factor V Leiden and antiphospholipid syndrome are also recognized contributors to central retinal vein occlusion8.
What a Retinal Vein Occlusion Feels Like
The classic story is easy to dismiss. A central retinal vein occlusion usually shows up as blurry or distorted vision in one eye that began suddenly, and it is typically painless8. Usually there is no redness and no ache. People often notice it on waking, or when they happen to cover the good eye. The lack of pain is why it gets ignored.
Blur is not the only way it shows up. With a central occlusion, sight can be lost in part or all of one eye, and you may notice floaters, which are dark spots, lines, or squiggles in your vision, with pain and pressure in the eye in severe cases4. Pain is the uncommon version of this, and it is a reason to be seen the same day rather than a sign that the eye is beyond help. With a branch occlusion, floaters can look like dark spots, lines, or squiggles, and the change may arrive over hours to days rather than at once5. A slow start does not make it harmless.
Plenty of harmless things blur vision. Dry eye blurs and then clears when you blink. Tired focus recovers with rest. Both tend to involve both eyes and to come and go. The occlusion pattern is different: one eye, a sudden start, and no pain8, and it does not clear on its own. If you cannot tell which one you have, treat it as the urgent one.
How Doctors Find a Retinal Vein Occlusion
Diagnosis starts with drops and a good look. An ophthalmologist does a dilated eye exam and an OCT scan, a light-based scan that measures retinal thickness, to look for swelling4. In a central occlusion, the exam often shows bleeding spread widely across the retina along with dilated, twisting veins, and it may also show small pale patches called cotton wool spots and a swollen optic nerve head8. Dilation blurs near vision for a few hours, so bring sunglasses.
Sometimes the exam needs a map of blood flow. Testing may include fluorescein angiography, where a dye is injected into an arm vein and photographed as it fills the retinal vessels, or OCT angiography, which images flow without dye4. These tests show how much retina has lost its blood supply, which is what predicts the outlook.
Your age changes what the diagnosis means. Younger patients may have blood clotting tests4. Screening for clotting disorders is advised for people under 50, for occlusion in both eyes, and for a personal or family history of clots. It includes tests such as protein C, protein S, factor V Leiden, and antiphospholipid antibodies8. Your hormone prescription is part of that history, so mention it early.
Treatment After the Diagnosis
Treatment targets the swelling, not the clot. The Academy's practice guideline states that the first line of treatment for macular swelling from a retinal vein occlusion is anti-VEGF therapy, medicine injected into the eye that blocks the growth signal driving the leakage9. The injection is done with numbing drops and takes a few minutes, and it is usually repeated on a schedule your specialist sets.
Other tools cover what injections alone do not. Options include anti-VEGF injections, steroid injections, or laser surgery such as panretinal photocoagulation, and it usually takes a few months after treatment before vision improves4. For branch occlusions, the goal of treatment is to reduce the swelling, and in most cases anti-VEGF injections or focal laser treatment do that, while steroid injections or steroid implants may be an option for people who do not improve with anti-VEGF5. Each option carries its own trade-offs, which your retina specialist will walk you through.
This decision belongs to your prescriber and you. The FDA-required labeling directs that a combined pill be stopped and retinal vein clotting evaluated right away when there is unexplained vision loss1. In practice a combined pill is usually paused while the eye is worked up, and what replaces it depends on your clotting results. In a large US insurance-claims study, by contrast, the rate of retinal vein occlusion in women who filled a menopause hormone therapy prescription was not detectably different from the rate in women who did not, over a median follow-up of about 6 months3.
Risks, Complications, and the Realistic Outlook
The outlook depends on how much sight you start with and how much retina lost its blood supply. About 7 of every 10 central occlusions are the non-ischemic type, which carries the better outlook. Eyes seeing 20/60 or better at the start tend to hold that level, while eyes worse than 20/200 tend to do poorly8. These are group averages, not a forecast for your eye.
The complication that drives the follow-up schedule is new vessel growth. New vessels on the iris develop in about two-thirds of ischemic central occlusions, usually between 2 and 4 months after the blockage8. Central occlusions carry a higher risk of front-of-the-eye vessel growth and glaucoma than branch occlusions9. This is treatable when caught early, which is the whole reason for close visits in the first months.
A retinal vein occlusion is a message about your circulation, not only your eye. People who have had any retinal vein occlusion carry an increased risk of heart and blood vessel events, and of death from any cause9. That sounds frightening, and the useful response is concrete. Get your blood pressure, blood sugar, and lipids checked and treated.
When to Call, and Which Doctor to See
Do not wait for a routine slot if any red flag from the top of this page appears. A sudden change in one eye, a curtain or shadow, a shower of new floaters, or a bad headache with a vision change all warrant a call the same day. If you started or restarted a combined method in the last few months, say so on the phone, because the risk of a venous clot is highest in the first year of use, and after restarting following a break of 4 weeks or longer1.
Start with whoever can see you fastest, an optometrist or an ophthalmologist, since both can dilate and spot the problem. Ongoing care belongs with a retina specialist, an ophthalmologist trained in diseases of the back of the eye. Your prescribing clinician handles the hormone side, so ask the eye clinic to send its notes there directly.
Common Questions About Hormones and Retinal Vein Occlusion
Not on your own, and usually not at all if you have no clotting risk factors. The measured increase is small: roughly 5 extra retinal vein occlusions for every 1,000,000 women using hormonal contraception for a year2. Stopping without a plan carries a real risk of unintended pregnancy, and pregnancy raises clot risk too. Ask your prescriber whether a lower estrogen dose or an estrogen-free method fits you better.
It does not appear to. In the Danish cohort, hormonal intrauterine devices showed no increased rate of retinal vein occlusion2. The likely reason is that these devices release progestin locally, with little estrogen effect on the body's clotting balance. That is why an intrauterine device is often the first suggestion for someone who cannot take estrogen.
A large US claims study found no detectable rise in eye risk. Across 205,304 women filling a hormone therapy prescription and 755,462 comparison women, there was no detectable difference in the rate of retinal vein occlusion or retinal artery occlusion3. That is reassuring for the retina in particular. Hormone therapy has other risks and benefits that belong in a wider talk with your clinician.
That is a shared decision, and it depends on why the occlusion happened. A history of clotting disorders and of prior clots appears among the contraindications to combined pills in the FDA-required label1, so a combined method is often ruled out. Estrogen-free options are usually still open. Bring your clotting results and the eye clinic's notes to the appointment.
It happens, but it is rare. Oral contraceptive use appears among the recognized contributors to central retinal vein occlusion, alongside clotting conditions such as factor V Leiden and antiphospholipid syndrome8. Because more than one factor is often at work, the workup in a younger person looks for an undiagnosed clotting tendency as well.
The available data suggest it does. Pills with 30 to 40 micrograms of estrogen showed about 1.6 times the rate of retinal vein occlusion, while 20 microgram pills showed no measured increase2. That is one study rather than a body of evidence, so treat it as a fair question to raise, not a rule. If you are on a lower dose product and doing well, this is not a reason to switch.
More Questions About Clots, Symptoms, and Follow-Up
Aim for the same day, and do not talk yourself into waiting until morning. Sudden painless blur in one eye is the classic sign of a retinal vein occlusion, and the exam that rules it in or out is quick. If you cannot reach an eye clinic, an emergency room can start the evaluation.
Often partly, and how much depends on the type and on where you start. Eyes seeing 20/60 or better at the first visit tend to keep that level, while eyes worse than 20/200 generally do not recover well8. After treatment it usually takes a few months before vision improves4. No one can promise a particular outcome for your eye.
Extra eye scans are not part of routine contraception care, and the absolute risk here is low enough that routine imaging would find very little. Keep the eye exam schedule your eye doctor sets, and get your blood pressure checked regularly, since high blood pressure carries close to three times the odds of retinal vein occlusion in pooled population data6. Knowing the warning signs is the part that changes outcomes.
Because a clotting tendency changes decisions well beyond your eye. Screening is advised in people under 50, in occlusion affecting both eyes, and where there is a personal or family history of clots8. A positive result can affect contraception, pregnancy planning, and care around surgery. A normal result is useful too.
Bring this list to the appointment and write the answers down.
- Which type of occlusion do I have, branch or central, and is it the ischemic type?
- How much of my retina has lost its blood supply, based on the angiography?
- Should my current hormonal method be paused, changed, or continued, and who decides?
- Do I need clotting blood tests, and what would a positive result change?
- How often do I need to be seen over the next 4 months, and what are you watching for?
- What blood pressure, blood sugar, and lipid targets should I be working toward?
- Which symptoms should send me back before my next scheduled visit?
- US FDA-required product labeling via DailyMed, National Library of Medicine (2022). Cryselle (norgestrel and ethinyl estradiol tablets) prescribing information.
- American Journal of Ophthalmology (nationwide Danish register cohort; Niazi S, Gnesin F, Jawad BN, et al.) (2025). Hormonal Contraception and Retinal Vascular Occlusion Risk.
- JAMA Ophthalmology (US insurance-claims cohort; Song D, Nadelmann J, Yu Y, VanderBeek BL) (2021). Association of Retinal Vascular Occlusion With Women Filling a Prescription for Female Hormone Therapy.
- American Academy of Ophthalmology, EyeSmart patient education (2024). What Is Central Retinal Vein Occlusion?.
- American Academy of Ophthalmology, EyeSmart patient education (2024). What Is Branch Retinal Vein Occlusion?.
- Journal of Global Health (Song P, Xu Y, Zha M, Zhang Y, Rudan I) (2019). Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors.
- Ophthalmology (pooled individual-participant analysis of 15 population-based studies; Rogers S, McIntosh RL, Cheung N, et al.) (2010). The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia.
- StatPearls, NCBI Bookshelf (Blair K, Czyz CN) (2023). Central Retinal Vein Occlusion.
- American Academy of Ophthalmology, Retina/Vitreous Preferred Practice Pattern Panel (2024). Retinal Vein Occlusions Preferred Practice Pattern.